Bispecific Antibody Deals Up 1800% in 2026 — The Data

Nineteen bispecific antibody deals closed between February 24 and August 24, 2026 — an 1800% increase over the single deal recorded in the prior six-month window. This is not a gradual warming trend. This is a land grab. Big Pharma is paying unprecedented premiums to secure bispecific assets, and the velocity suggests that the modality has crossed from "promising platform" to "must-have pipeline filler" in the strategic calculus of companies facing patent cliffs and oncology portfolio gaps.

The Data — Bispecific Antibody Deal Activity, Period over Period

One deal in six months followed by 19 in the next six. The base is small, which inflates the percentage — but the absolute number is what matters here. Nineteen bispecific transactions in a single half-year is, by any historical standard tracked in Deal Benchmarks, a record for this modality class. For context, DealForma tracked roughly 12–15 bispecific deals across all of 2024. We blew past a full year's volume in half the time.

What's Driving the Trend

Three forces converged to produce this surge, and none of them are temporary.

First, clinical validation has stacked up. The FDA approved four bispecific antibodies between late 2022 and mid-2025 — Mosunetuzumab, teclistamab, glofitamab, and epcoritamab — all in hematological malignancies. These weren't niche curiosities; they posted meaningful response rates in relapsed/refractory populations and demonstrated that the bispecific format could achieve durable clinical outcomes. That approval cluster removed the platform risk that historically depressed bispecific deal valuations relative to conventional monoclonal antibodies. Pharma BD teams no longer need to sell internal committees on whether bispecifics "work." The question has shifted to which targets, which formats, and who has the best manufacturing scalability.

Second, Big Pharma patent cliffs are accelerating urgency. Pfizer's aggressive positioning — committing over $12.5B in total deal value to 3SBio in July alone — reflects a company that lost Ibrance exclusivity headroom and needs to reload its oncology portfolio at scale. Pfizer is not alone. AbbVie, Roche, Amgen, and J&J all face LOE pressures on major franchises through 2028–2030. Bispecifics represent a modality where meaningful differentiation is still achievable, unlike the increasingly crowded ADC space where 80+ programs compete for the same targets. The bispecific antibody licensing 2026 environment is defined by this urgency: buyers are moving fast and paying up because the cost of inaction — an empty late-stage pipeline — is existential.

Third, platform maturation has lowered execution risk. Companies like CytomX, AbCellera, and 3SBio have built engineered bispecific platforms that address the historical challenges of this format: manufacturing complexity, short half-life, and cytokine release syndrome. CytomX's Probody bispecific approach — which Amgen licensed in June 2026 — adds conditional activation to the bispecific toolkit, potentially widening the therapeutic window in solid tumors. These aren't first-generation constructs anymore. The platforms have caught up to the ambition.

Notable Deals

The Pfizer-3SBio pairing dominates this dataset and deserves scrutiny. Two separate transactions within six days, totaling $2.5B in upfront payments and $12.55B in combined total deal value. These are not option deals or early-stage bets — these are conviction-level commitments. The upfront-to-TDV ratio on the first deal ($1.3B / $6.35B = ~20.5%) signals that Pfizer is willing to bear significant near-term cash outlay for late-stage or differentiated bispecific assets. That ratio sits well above the historical 10–15% average tracked in our Deal Benchmarks for oncology licensing agreements, confirming this is a seller's market for quality bispecific programs.

The AbCellera-Jazz deal is structurally interesting. Jazz Pharmaceuticals — not a traditional oncology powerhouse — committed $4B in total deal value to access AbCellera's bispecific capabilities. This signals that bispecific demand has expanded beyond the top-10 pharma buyers into the mid-cap specialty pharma tier. When companies like Jazz start competing for bispecific assets, the pool of potential acquirers for biotech licensors widens meaningfully — and that deepening buyer pool supports sustained valuation inflation.

CytomX's Amgen deal, while smaller in disclosed terms ($40M upfront), represents a platform access play. Amgen is not buying a single molecule; it is licensing CytomX's Probody bispecific technology to apply across its own target portfolio. These platform-level partnerships often generate more long-term value than single-asset deals but are harder to benchmark because milestone structures are opaque. BD teams evaluating similar platform-out transactions should use Solidus to stress-test milestone probability assumptions — the gap between headline TDV and risk-adjusted value is especially wide in platform deals.

What This Means for BD Teams Right Now

If you're selling bispecific assets, this is the most favorable licensing environment in the modality's history. Upfront payments are compressing toward 20%+ of TDV for differentiated programs. Competitive tension among buyers is real — Pfizer, Amgen, Jazz, and others are all in-market simultaneously. If you have a bispecific program with Phase 1b+ data in a validated target class (BCMA, CD3, GPRC5D, HER2×HER3), you have leverage to demand higher upfronts, co-promote rights, or opt-in structures that were unrealistic 18 months ago.

If you're buying, speed matters more than perfect diligence. The 19-deal surge in six months means the best assets are being swept off the market at pace. Waiting for Phase 2 data to de-risk your decision is a luxury that may cost you the deal entirely. The practical implication: BD teams need pre-negotiated term sheets and fast-track governance approval paths for bispecific transactions. Deals that take 9–12 months to close will lose to competitors who can execute in 4–6.

Structurally, upfronts are the new battleground. When multiple buyers are competing for the same bispecific asset, milestone-heavy structures are losing to upfront-heavy proposals. Sellers are rationally discounting back-loaded milestones and selecting partners who demonstrate commitment through immediate cash. If your deal model relies on a $50M upfront with $3B in biobucks, you're bringing a knife to a gunfight in the current bispecific antibody deal trends 2026 environment. Benchmark your deal against current market rates using the Ambrosia calculator before entering negotiations — the spread between market and your internal assumptions may surprise you.